Negative immunolabeling for αSMA and S-100 excludes the presence of myogenic or neurogenic cells, thereby ruling out a diagnosis of soft tissue sarcoma (Sloboda & Faria Júnior, 2022). This evidence concerns the gene ACTA1 and soft tissue sarcoma.